Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.87 USD | +1.21% | -3.32% | +17.88% |
May. 28 | Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024 | CI |
May. 08 | Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000 | MT |
Financials (USD)
Sales 2024 * | 5.19M | Sales 2025 * | 6.25M | Capitalization | 1.69B |
---|---|---|---|---|---|
Net income 2024 * | -177M | Net income 2025 * | -205M | EV / Sales 2024 * | 268 x |
Net cash position 2024 * | 302M | Net cash position 2025 * | 122M | EV / Sales 2025 * | 251 x |
P/E ratio 2024 * |
-9.54
x | P/E ratio 2025 * |
-8.93
x | Employees | 141 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.64% |
1 day | +1.21% | ||
1 week | -3.32% | ||
1 month | -16.88% | ||
3 months | -30.56% | ||
6 months | +54.48% | ||
Current year | +17.88% |
Managers | Title | Age | Since |
---|---|---|---|
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 15-11-30 |
Keith Regnante
DFI | Director of Finance/CFO | 54 | 20-01-31 |
Jennifer Lachey
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 20-12-16 |
Carl Gordon
CHM | Chairman | 59 | 20-02-29 |
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 15-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.03% | 1,487 M€ | +7.77% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 46.87 | +1.21% | 405,420 |
24-05-30 | 46.31 | -0.88% | 237,257 |
24-05-29 | 46.72 | -4.16% | 271,812 |
24-05-28 | 48.75 | +0.56% | 249,730 |
24-05-24 | 48.48 | -1.38% | 140,361 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.88% | 1.69B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- KROS Stock